病毒唑加庆大霉素雾化吸入联合开瑞坦治疗亚急性咳嗽的临床观察

Effects of ribavirin plus gentamicin atomization inhalation combined with loratadine in treatment of subacute cough

目的观察病毒唑加庆大霉素雾化吸入联合开瑞坦治疗亚急性咳嗽临床疗效。方法选择上呼吸道感染后的亚急性咳嗽患者101例随机分为治疗组51例和对照组50例。治疗组给予病毒唑加庆大霉素雾化吸入联合开瑞坦口服治疗；对照组给予常规抗生素联合开瑞坦口服的经验治疗。治疗5～7d后观察并比较2组临床疗效和不良反应。‘结果治疗组总有效率为94．12％，高于对照组的78％，且疗程短，临床症状改善快，不良反应少，差异有统计学意义（P〈0．05）。结论病毒唑加庆大霉素雾化吸入联合开瑞坦用于上感后亚急性咳嗽疗效显著。

Objective To evaluate the therapeutic effects of ribavirin plus gentarnicin atomization inhalation combined with loratadine in the treatment of subacute cough. Methods A total of 101 patients with subacute cough after upper respiratory tract infection were randomly divided into a treatment group （ n = 51 ） and a control group （ n = 50）. The treatment group received the treatment of ribavirin plus gentamicin atomization inhalation combined with loratadine oral; the control group received the experience treatment of conventional antibiotics combined with loratadine oral. After 5-7 days, the clinical efficacy and adverse reactions of the two groups were observed and compared. Results The effective rate of the treatment group was 94.12%, higher than that of the control group of 78%. In the treatment group, there was a short treatment course, the clinical symptoms improved rapidly, and there was less adverse reaction, and there were significant differences between the two groups （P 〈 0.05）. Conclusions The therapy of ribavirin plus gentamicin atomization inhalation combined with loratadine is effective in the treatment of subacute cough after upper respiratory tract infection.